Vetter investment will enhance strategic partnership
Start of construction for modern center for visual inspection and logistics
A groundbreaking ceremony was held for Vetter’s newest facility, Ravensburg Vetter West. Vetter will build a state-of-the-art high bay warehouse for cold-storage and room-temperature goods. Space will also be dedicated for automatic and manual visual inspection as well as for stability chambers designed to the highest standards. The new facility will allow the company to optimize both its control and logistical processes, which will enable safe and expeditious product delivery to customers. To power the new facility, Vetter will use mostly renewable energy, from photovoltaic cells, biogas and geothermal sources. The first construction phase, scheduled for completion by the end of 2011, is estimated to cost more than 30 million Euros.
“Our investment in a state-of-the-art center for visual inspection and logistics is an investment in our partnership with customers worldwide,” says Vetter Managing Director Thomas Otto. “The facility will broaden the base for our global market supply and underscores our dedication to staying at the forefront of technology.” A highly efficient floor plan and optimized personnel and material flows enable the greatest level of product safety. End-to-end material tracking ensures optimized processes and high traceability. Specially secured storage rooms for visual inspection help prevent product mix-ups and cross-contamination.
The new centre will meet environmental standards as well. Once completed, the new facility will use mainly renewable energy. The storefront will be equipped with photovoltaic cells; for climate control of storage rooms, Vetter will harness geothermal energy, a biogas-fired block heat and power plant and excess energy.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Palmitoylation, a new target for anti-cancer drugs - By developing a tool to visualize the membrane association and activation status of normal and oncogenic proteins, scientists at the UNIGE have established the basis for innovative drug discovery

Dr. Cecil B. Pickett joins the GVK Biosciences Scientific Advisory Board
Photocure’s Cevira shows positive interim results for treatment of precancerous lesions of the cervix - Six-month interim data presented at international conference addressing prevention of cervical cancer
Horizon Discovery Announces Strategic Partnership with Promega to Develop Next-Generation Predictive Human Disease Models

Triple-threat cancer-fighting polymer capsules for guided drug delivery created
New prostate cancer treatment may be riskier
Genzyme and Bayer HealthCare Enter New Strategic Agreement - Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis

Billion-euro takeover: Roche joins the fight against obesity
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Immune system reveals new ways to treat brain disease and pain
Genomatix partners with Research Instruments Pte Ltd for Singapore, Malaysia and Thailand markets
